Head and neck squamous cell cancer Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user laughing with her husband while making lunch.
Potential OPDIVO® (nivolumab) user laughing with her husband while making lunch.

Clinical trial results for
previously treated
head and neck
squamous cell cancer

For adults with squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread after previous treatment

Actor portrayals.

An FDA-approved immunotherapy that helped people live longer compared to standard therapy options (cetuximab, methotrexate, or docetaxel)

About the clinical trial

In a clinical trial of 361 people with previously treated squamous cell carcinoma of the head and neck (SCCHN) that had returned or spread, 240 people were given OPDIVO and 121 people were given standard therapy options that included cetuximab, methotrexate, or docetaxel.

More people given OPDIVO were alive at 1 year compared to standard
therapy options

36% of those given OPDIVO® were alive at 1 year, versus 17% given standard therapy options.

People given OPDIVO lived longer compared to standard therapy options

At 8 months, half the people given OPDIVO® were alive.
OPDIVO

Half the people were alive

At 5 months, half the people given standard therapy options were alive.
Standard Therapy Options (cetuximab, methotrexate,
or docetaxel)

Half the people were alive

In the clinical trial, people given OPDIVO had a 30% lower risk of dying than those given standard therapy options that included cetuximab, methotrexate, or docetaxel.

OPDIVO will not work for everyone. Individual results may vary.

“When people think that there’s no hope for them, there is.”


Terry’s story

Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment journey with OPDIVO for his previously treated squamous cell carcinoma of the head and neck (SCCHN).

Terry shares his experience with OPDIVO® (nivolumab) for squamous cell carcinoma of the head and neck.
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For people with previously treated squamous cell carcinoma of the head and neck

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.